

# SeQuent Scientific announces another strong performance

## Q3 FY 19 Revenues up by 20%

## Q3 FY 19 EBITDA up by 57%

**Mumbai, February 1, 2019:** SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the quarter and nine months ended December 31, 2018.

### Financial Highlights

All values in ₹mn

Particulars	Q3FY19	Q3FY18	Growth (%)	9MFY19	9MFY18	Growth (%)
Revenues	2,705	2,249	20%	7,574	6,167	23%
EBITDA	355	226	57%	924	563	64%
EBITDA %	13.1%	10.0%	310bps	12.2%	9.1%	310bps
PAT	130*	-58		315	-24	

\*Adjusted PAT for Q3FY19 stood at Rs.162 Million, after adjusting for net impact of exchange arisen due to MTM accounting of inter company dollar denominated debt for Turkey operations. Details in slide 14 of attached earnings presentation.

Commenting on the Q3FY19 results, **Manish Gupta, Managing Director of SeQuent Scientific Limited** said: "This has been another quarter of consistent performance wherein our Revenue and EBITDA grew by 20% and 57% respectively, with a 310 bps margin improvement. The all-round growth was fueled by execution excellence across both APIs and formulations.

Strategically, this was an important quarter as we filed our first in-house developed injectable in EU and completed first new product validation of a valuable injectable at Bremer site in Germany.

With the operating leverage playing out, our return ratios are improving consistently and we stay on track to create sustainable value for our stakeholders."

Detailed presentation on the performance forms part of this press release.

### Earnings Call with Investors

The Company will conduct an Earnings call at **3:00 PM IST on February 01, 2019** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

## About SeQuent Scientific Limited

---

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

**For details, feel free to contact:**

---

### **Tushar Mistry**

Chief Financial Officer

Tel: +91 22 4111 4717

[tushar.m@sequent.in](mailto:tushar.m@sequent.in)

### **Shivangi Bubna**

Christensen Investor Relations

Tel : +91 22 4215 0210

[sbubna@christensenir.com](mailto:sbubna@christensenir.com)

### **Registered Office**

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: [www.sequent.in](http://www.sequent.in)

### **Abhishek Singhal**

Investor Relations Consultants

[abhishek.s@sequent.in](mailto:abhishek.s@sequent.in)

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*